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Abstract
Background: We investigated a South African family of admixed ancestry in which the first generation (G1) developed
insidious progressive distal to proximal weakness in their twenties, while their offspring (G2) experienced severe
unexpected symptoms of myalgia and cramps since adolescence. Our aim was to identify deleterious mutations that
segregate with the affected individuals in this family.
Methods: Exome sequencing was performed on five cases, which included three affected G1 siblings and two
pauci-symptomatic G2 offspring. As controls we included an unaffected G1 sibling and a spouse of one of the G1
affected individuals. Homozygous or potentially compound heterozygous variants that were predicted to be functional
and segregated with the affected G1 siblings, were further evaluated. Additionally, we considered variants in all genes
segregating exclusively with the affected (G1) and pauci-symptomatic (G2) individuals to address the possibility of a
pseudo-autosomal dominant inheritance pattern in this family.
Results: All affected G1 individuals were homozygous for a novel truncating p.Tyr1433Ter DYSF (dysferlin) mutation,
with their asymptomatic sibling and both pauci-symptomatic G2 offspring carrying only a single mutant allele. Sanger
sequencing confirmed segregation of the variant. No additional potentially contributing variant was found in the DYSF
or any other relevant gene in the pauci-symptomatic carriers.
Conclusion: Our finding of a truncating dysferlin mutation confirmed dysferlinopathy in this family and we propose
that the single mutant allele is the primary contributor to the neuromuscular symptoms seen in the second-generation
pauci-symptomatic carriers.
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Background
Dysferlinopathies are a group of autosomal recessive
muscular dystrophies caused by mutations in the dysferlin
gene, DYSF [1, 2], and is typified by markedly reduced or
absent dysferlin protein on immunohistochemical staining
in muscle [3]. It most frequently presents as a distal my-
opathy affecting first the posterior distal leg compartment
(Miyoshi muscle dystrophy), limb-girdle muscle dystrophy
(LMGD2B) and a combination of the aforementioned,
“proximodistal” myopathy [4, 5]. Clinical manifestations
can be significantly varied even between individuals in a
family bearing the same mutation, which indicates a pos-
sible role for genetic modifiers [6–8].
A definitive diagnosis of dysferlinopathy can only be
made when pathogenic mutations are identified in the
large (>233Kbp, 58 exons, >6Kbp coding sequence) dysfer-
lin (DYSF) gene [9], which lacks mutation hotspots. It was
recently demonstrated that next generation sequencing
(NGS) targeting the coding regions of the DYSF gene en-
ables efficient and accurate genetic diagnosis of dysferlino-
pathy [10]. Whole exome sequencing (WES), however,
may provide additional advantages as an unbiased diag-
nostic strategy in families requesting a definitive diagnosis
and genetic counselling [11], particularly in atypical
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disease presentations and/or when unexpected phenotypes
are suspected.
We present an exome sequencing study in a non-con-
sanguineous family actively seeking a diagnosis for the
neuromuscular symptoms experienced by themselves
and their children over a period of 25 years. The first
generation (G1) presented with a predominant distal
‘posterior calf ’ myopathy starting in early adulthood.
This was suggestive of classical autosomal recessive
Miyoshi myopathy caused by compound heterozygous
or homozygous dysferlin gene mutation(s), since neither
of their parents had been diagnosed with muscular dys-
trophy. However, at least five of the second generation
(G2) offspring had been attending neurological services
with mainly exercise-induced muscle cramps over a num-
ber of years starting in adolescence.
Methods
Patients and clinical evaluations
The study and subject consent forms were approved by
the University of Cape Town Health Sciences faculty
human ethics research committee (REF 552/2013) and
the study carried out in accordance with the approved
guidelines and regulations. We studied two generations
of a South African family of mixed genetic ancestry that
likely includes ancestors from Africa, Europe as well as
Madagascar and Java as previously described [12]. Fam-
ily members of G1 and G2 had been attending the adult
and paediatric neurology clinics attached to the Univer-
sity of Cape Town for 25 years. After signed informed
consent, blood was obtained for WES from G1 individ-
uals, three affected (I-2, I-4 and I-5), one unaffected
sibling (I-1) and one unrelated unaffected family mem-
ber (I-3) as controls, and two members from G2 with
neuromuscular symptoms and areflexia, II-2 and II-5.
Structured folder reviews were performed to obtain
previous examination details, laboratory data including
those of muscle biopsies and clinical electrophysio-
logical studies.
Whole exome capture, sequencing and variant calling
Paired-end exome sequencing was performed at 50×
coverage by CLIA accredited Otogenetics Corporation,
Norcross, GA, USA using the Agilent SureSelect Human
V5 + UTR capture kit and the Illumina HiSeq2000/2500
platform. After quality control, reads for each patient
were aligned to the hg19 human reference genome using
NOVOALIGN [13], PCR duplicates were removed using
Picard [14], followed by indel realignment and base quality
score recalibration, variant calling and quality evalu-
ation using the Genome Analysis ToolKit [15] version
3.6 to produce a high-confidence set of variants for
each sample.
Identification of likely function-impacting candidate
variants
Variants were annotated using ANNOVAR [16] and were
filtered based on both autosomal recessive and dominant
inheritance models. For the recessive model, we identified
variants that were homozygous in the three affected
G1 siblings, wild-type in their unaffected sibling, and
wild-type or heterozygous in the unrelated unaffected
family member and the G2 offspring. For the autosomal
dominant model, we identified variants that were hetero-
zygous in all the affected/pauci-symptomatic family mem-
bers, and where both related and unrelated controls were
wild-type. For initial filtering, variants with a minor allele
frequency > 1% in public databases, namely the 1000
Genomes Project [17], the NHLBI-ESP 6500 Exome Se-
quencing Project [18] and the Exome Aggregation Con-
sortium [19] databases were filtered out, as were those
present in the currently unreleased Southern African
Human Genome Program [20] variant dataset. Nonsense,
frameshift and splicing variants were automatically selected
as preliminary candidates, while missense variants were
further evaluated if they passed the recommended dele-
teriousness score thresholds for any one of FATHMM
[21] or the MetaSVM and MetaLR ensemble prediction
methods [22].
Results
Clinical findings
Three affected individuals from G1 had developed progres-
sive muscle weakness in their twenties, two of whom also
had prominent exercise-induced myalgia, and five individ-
uals from the second generation developed neuromuscular
symptoms in adolescence (Fig. 1). Two individuals from
G1 (I-4 and I-5) presented with the distal Miyoshi muscle
dystrophy phenotype and one (I-2) with a “proximodistal”
phenotype. Two cases from G2 had areflexia and margin-
ally raised CK (II-2 and II-5), and three (II-1, II-6, II-7 and
II-8) had normal reflexes. Individuals I-1, II-3, and II-4 had
no neuromuscular symptoms or signs. The offspring of
1–1 were asymptomatic adults, and those of I-4 had
not reached adolescence and were not examined.
The index case (I-4), first examined at age 26, com-
plained of two years of progressive thinning of the distal
legs and quadriceps, an inability to stand on his toes,
and myalgia in his legs aggravated by exercise. Later, he
noticed weakness in the hands. The clinical presentation
was a distal, posterior compartment muscular dystrophy
with markedly raised creatine kinase (CK) levels (> 47×
upper limit of normal (ULN)). However, the tendon re-
flexes were either absent (legs) or reduced (arms), and
four years later all the reflexes were absent. Electrophysi-
ology showed normal nerve conductions, and myopathic
features on needle electromyography (EMG). Electro-
cardiography was normal. A deltoid muscle biopsy
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confirmed a dystrophic process without inflammatory
infiltrates; no special staining was available. At that
time, his two asymptomatic sisters (one was Case I-5,
aged 21, see below) and mother were noted to have
normal CK levels (CK ≈ 61 IU/L; N = 26–140 IU/L), al-
though his father, aged 51, complained of muscle
cramps and had a slightly raised CK level (249 IU/L)
which was 1.5× above the upper level of normal expected
for age and sex. Approximately 15 years after symptom
onset, I-4 required bilateral crutches to mobilize, and
10 years later became wheelchair bound. The pattern of
weakness had progressed to severe limb girdle and distal
weakness. Although sensation was previously recorded as
intact, the last examination at age 49 showed evidence of
a mild sensory stocking neuropathy.
Case I-2 presented at age 29 with a history of progressive
leg weakness since mid-twenties, noting difficulty climbing
stairs, getting up from chairs and exercise-induced
muscle cramps, especially in his calves. His examin-
ation showed wasting of the biceps and distal legs, mild
proximo-distal posterior leg weakness, and reduced/
absent reflexes. Later he exhibited a waddling gait. The
CK level was 20× ULN. A muscle biopsy at age 40
showed features of muscle dystrophy and immunohis-
tochemistry showed absence of dysferlin in the pres-
ence of positive merosin, emerin, caveolin, dystrophin
and sarcoglycan staining. Fifteen years later he required
crutches to mobilize.
Case I-5 presented at age 34 with increasing difficulty
in walking, climbing stairs, rising from a seated position,
and general muscle fatigue since her late twenties. The
arms showed tapering distally and the posterior compart-
ment of the legs, marked wasting. Her tendon reflexes
were globally depressed and there was marked weakness
of the posterior compartment leg muscles. Her CK level
was > 30× ULN. A muscle biopsy of the left biceps showed
similar results to her brother except that dysferlin staining
was initially present and dystrophin was absent, but the
positive control (spectrin) showed partial staining. Her
disability increased substantially and at age 45 years she
was largely confined to a wheelchair. A repeat biopsy of
the right biceps showed absent dysferlin staining.
II-2 was examined at age 18 years. He had normal
early motor development but was noted to fall more
than usual as a child whilst running. Muscle cramps and
stiffness, especially with physical activity, was noted
during early adolescence. At age 15 he had increasing
difficulty with riding his bicycle, climbing stairs as well
as gait instability and stopped playing sport. He fell fre-
quently. The neurological examination showed mild
wasting of the biceps despite well-developed muscles
elsewhere. His tendon jerks were absent. Power testing
ASO (yrs)
3
27 24 29
I:1 I:2 I:3 I:4 I:5
DYSF
DYSF
+/-
+/- +/-
3 II:1 II:2 II:3 II:4 II:5
+/+ -/- +/+ +/+
II:6 II:7 II:8
neuromuscular symptoms + areflexia + CK > ULN
neuromuscular symptoms; normal reflexes
muscular dystrophy
Fig. 1 Family pedigree and validated genotypes for the novel DYSF stop gain variants. Circles represent females and squares represent males.
White figures (excluding triangles) symbolize unaffected members; solid symbolize disease cases, striped represent cases with neuromuscular
symptoms, areflexia and elevated creatine kinase (CK) levels above the upper limit of normal (ULN); and speckled symbolize cases with neuromuscular
symptoms but normal deep tendon reflexes. Individuals denoted by triangles were of uncertain clinical status and “/” indicate deceased individuals.
ASO refers to age at symptom onset in years (yrs). Generation 1 (G1) refers to I:1 to I:5 and G2 refers to II:1 to II:8. DYSF refers to the dysferlin gene. ‘+’
refers to the presence of the DYSF mutation, ‘-‘to wild-type DYSF, +/− refers to heterozygous individuals and +/+ to homozygous individuals
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was normal, but he had a mild waddling gait. Sensation
and coordination testing were normal. Clinical electro-
physiology was refused. The CK level was at the upper
the limit of normal (ULN) for his age (218 IU/L).
II-5 had experienced muscle pain, and episodes of cramp
and stiffness lasting several hours to 1–2 days since the age
of 12–13 years. These symptoms were, and still are, aggra-
vated by physical activity. Since his early twenties he has also
noticed increasing clumsy ankles and occasional give-in
weakness of the legs. Examination at age 25 showed floppy
ankles but no obvious wasting in his hands or feet. His ten-
don reflexes were globally absent and he had mild weakness
of toe flexors but not of the plantar flexors. The remaining
motor, sensory (all modalities) and coordination systems
were normal. The CK level was slightly elevated (193 IU/L;
1.1× ULN for age and sex). Nerve conduction studies were
normal. EMG of the medial head of gastrocnemius showed
no spontaneous activity and normal motor units.
Cases II-1, II-6, II-7 and II-8 had been experiencing
neuromuscular symptoms since the ages of 12 to 13 years,
mainly myalgia, stiffness and/or muscle cramps. These
symptoms occurred either in the hands or legs and were
frequently provoked by mild physical activity including
writing with a pen or walking upstairs, respectively.
Exome sequencing and filtering for candidate deleterious
variants
WES was performed on I-2, I-4 and I-5 from G1, one
unaffected sibling (I-1) and one unrelated unaffected
family member (I-3) as controls, and on two members
from G2 with neuromuscular symptoms and areflexia,
II-2 and II-5. Approximately 50,000 variants were identi-
fied for each individual. Six variants segregated with all
three symptomatic G1 individuals using the recessive
model, of which three were in exonic regions, and one
each in a 3′-untranslated region (UTR), intronic and
intergenic regions, respectively. A novel nonsense C >G
mutation located at position 4299 in exon 39 (NCBI
RefSeq: NM_003494) of the dysferlin gene (DYSF) was
identified as responsible for the family’s muscular dys-
trophy after filtering out common variants and those not
predicted to impact protein function. Sanger sequencing
confirmed the mutation to be homozygous in affected
individuals of G1, and carrier status in I-1, II-2 and II-5.
The p.Tyr1433Ter (NP_003485.1) mutation results in
the loss of the sixth (C2E) and seventh (C2F) domains of
the dysferlin protein (Fig. 2).
No other potentially deleterious dysferlin variant was
found in the exomes of the two pauci-symptomatic G2
DYSF-mutant carriers. As they also presented with neuro-
muscular symptoms and areflexia in absence of distinct
myopathy, we further filtered for rare or novel variants pre-
dicted to impact protein function that segregated exclu-
sively with symptomatic individuals in both G1 and G2.
Only two novel heterozygous missense mutations were
identified in the LRP2 (low density lipoprotein-related pro-
tein 2) and GXYLT1 (glucoside xylosyltransferase 1) genes,
which have no known roles in neuromuscular disease.
Fig. 2 Protein level consequence of the identified novel stop-gain dysferlin gene (DYSF) mutation. The diagram illustrates the loss of two C2
domains in DYSF gene due to the identified novel stop-gain. The chromatogram illustrates the Sanger sequencing validation for mutant and
wild-type alleles in the affected and unaffected family members. The protein alignment illustrates the nonsense mutation and protein truncation
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Discussion
The G1 symptomatic individuals developed mainly distal
posterior compartment myopathy in their legs during
their early twenties with extremely high CK levels at the
time of diagnosis. The first generation’s symptoms were
indicative of Miyoshi myopathy/dysferlinopathy, since
neither of their parents was diagnosed with myopathy
even after age 60. Using WES, we confirmed autosomal
recessive dysferlinopathy in this South African family,
caused by a novel truncating p.Tyr1433Ter mutation in
the DYSF gene, which accounts for the muscle dystrophy
in the first generation. An asymptomatic G1 sibling also
carried one copy of the DYSF mutation.
Several of their offspring experienced neuromuscular
symptoms starting in adolescence to the extent that they
had been followed at the pediatric neurology service for
several years. The current study found that all the G2
cases with neuromuscular symptoms have only one copy
of the novel nonsense DYSF mutation and no other po-
tentially disease-causing variants in the gene. Although
we postulated that co-occurrence of another mutation in
a second gene could potentially be causing or contribut-
ing to the neuromuscular symptoms observed in G2, we
only found two novel heterozygous missense mutations
in the LRP2 and GXYLT1 genes, neither of which are
reasonable candidates based on their known cellular
functions and disease associations. We therefore suggest
that the single mutated DYSF allele could be responsible
for the less severe neuromuscular symptoms in G2.
Interestingly, of the two inferred heterozygous de-
ceased parents, the father apparently also complained
of neuromuscular symptoms (see Clinical Findings).
The observation of a single mutant allele in both un-
affected and pauci-symptomatic individuals suggests
that variable penetrance, and/or other unidentified modi-
fier allele(s), may underlie the manifestation of neuro-
muscular symptoms.
Fanin et al. [23] suggested in 2006 that carriers of
DYSF mutations could be at risk of developing a milder
phenotype and a number of reports have since contrib-
uted evidence to support this hypothesis. Two unre-
lated cases of DYSF mutation carriers presenting in
middle age with muscle weakness, elevated creatine
kinase, abnormal muscle MRI and reduced levels of
muscle dysferlin, have been reported [24]. Another case
of a bent spine syndrome/camptocormia, presenting in
the seventh decade, appears to be an unusual presenta-
tion of pauci-symptomatic dysferlinopathy based on a
heterozygous dysferlin mutation [25]. Another study
was able to support a diagnosis of primary dysferlinopa-
thy in symptomatic carriers with findings of abnormal
dysferlin gene expression in skeletal muscle and mono-
cytes [26]. Of note is that the two patients studied were
unrelated but carried the same mutated allele, which
suggests that certain mutations may have a higher like-
lihood than others of producing symptoms in carriers.
Conclusion
We confirm dysferlinopathy in this family due to a novel
truncating p.Tyr1433Ter DYSF mutation. Our report
highlights the importance of considering variable pene-
trance of heterozygous dysferlin mutations in the con-
text of pauci-symptomatic younger offspring.
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